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To determine if metabolic characteristics differed in women with and without polycystic ovary 
syndrome (PCOS) between a Caucasian and Middle East population. Comparative cross-sectional 
analysis. Demographic and metabolic data from Middle Eastern women from Qatar Biobank (97 with 
PCOS, 622 controls) were compared to a Caucasian PCOS biobank in Hull UK (108 with PCOS, 69 
controls). In both populations, PCOS women showed a worse cardiovascular risk profile of increased 
systolic and diastolic blood pressure, increased C-reactive protein (CRP), reduced HDL, insulin 
resistance as well as increased androgens compared to their respective controls without PCOS. UK 
women without PCOS had higher systolic and diastolic blood pressures, and increased testosterone 
results (p < 0.01) compared to Middle Eastern women without PCOS who had higher inflammatory 
markers (WBC and CRP), HDL and insulin resistance (p < 0.001). UK PCOS women had a higher body 
mass index, systolic and diastolic blood pressures, triglycerides (p < 0.01), whilst Middle Eastern PCOS 
women showed increased testosterone, free androgen index, HDL and CRP (P < 0.01). There was no 
difference in insulin or insulin resistance between the two PCOS cohorts. This study highlights ethnic 
population differences because, whilst cardiovascular risk indices were increased for both PCOS 
cohorts, this may be for different reasons: BMI, waist and hip measurements, systolic and diastolic 
blood pressure, and triglycerides were higher in the UK cohort whilst testosterone, HDL and CRP 
were higher in the Middle East population. Insulin resistance did not differ between the two PCOS 
populations despite differences in BMI.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder that affects 6 (NIH criteria) − 10% 
(Rotterdam and Androgen excess society guidelines) of reproductive aged-  women1,2 based on a Caucasian 
population. It has recently been shown that the prevalence based on the NIH criteria in Qatar in the Middle East 
may be higher than that of a Caucasian  population3. PCOS leads to irregular periods, infertility and increased 
androgen levels causing hirsutism and  acne4,5. Obesity affects the majority of women with PCOS, and they have 
a higher prevalence of both impaired glucose tolerance and type 2  diabetes6,7. Women with PCOS show increased 
cardiovascular risk through a higher incidence of hypertension, an adverse lipid profile, and insulin resistance 
(IR)8,9. Women with PCOS tend to have increased risk of cardiovascular disease, this risk seemingly increasing 
in relation to  age10. It has been reported that women with PCOS have deficient insulin signaling which leads to 
insulin resistance and increased risk of type 2 diabetes (T2DM)11.
Differences in phenotype and clinical symptoms of PCOS related to the clinical, hormonal, and metabolic 
characteristics among various ethnic backgrounds, including Hispanics, African Americans, Asians, and Indians, 
have been  described12,13. Differences in women of Middle Eastern origin have been described in comparison 
to Caucasian  women13, with Caucasian women reported as having a more adverse cardiovascular profile with 
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increased insulin  sensitivity14, though the populations were not age matched; however, others have not found 
this to be  so15.
From in silico analysis of the phenotype-genotype relationship, using single nucleotide polymorphisms 
determining the degree of genetic similarity, women from the Middle East are predicted to have a more severe 
hyperandrogenic  phenotype16, but there are no comparative studies detailing the differences and similarities 
between a Caucasian and a homogeneous Middle Eastern population; therefore this study was undertaken.
Methods
Middle Eastern cohort. As detailed  previously3 Qatar Biobank (QBB) https ://www.qatar bioba nk.org.qa is 
a large scale medical research initiative that aims to recruit 60,000 Qatari men and women aged ≥ 18 years. Fol-
lowing informed consent, extensive clinical phenotypic information was collected from each subject in addition 
to demographic, biochemical and genetic parameters that were approved by QBB IRB and the Ministry of Public 
Health in Qatar. 4500 subjects had been recruited aged between 18 and 89 years of age at the time of this study, 
of whom 719 Qatari women between the ages of 18–40 inclusive were included. Of those, 97 had PCOS and 622 
did not. The diagnosis of PCOS for the comparison within the QBB was based on the NIH criteria of biochemical 
evidence of hyperandrogenemia (free androgen index > 4.5) or a raised testosterone greater than 2.7 nmol/l, and 
oligomenorrhea or amenorrhea. All identified PCOS subjects had no documented concurrent illness and were 
not on any medication; any illness or medication were exclusion criteria for the study.
UK cohort. 177 Caucasian women, 108 with PCOS and 69 without, who presented sequentially to the 
Department of Endocrinology, Hull and East Yorkshire Hospitals NHS Trust were recruited to the local PCOS 
biobank (ISRCTN70196169). All patients gave written informed consent. The Newcastle & North Tyneside Eth-
ics committee approved this study. The diagnosis of PCOS was based on all three diagnostic criteria of the Rot-
terdam consensus, namely clinical or biochemical evidence of hyperandrogenism (Ferriman-Gallwey score > 8; 
free androgen index > 4.5 respectively), self-reported oligomenorrhea (≤ 9 menses per year) or amenorrhea (no 
menses for 3 months or more) and polycystic ovaries on transvaginal ultrasound (≥ 12 antral follicles in at least 
one ovary or ovarian volume of ≥ 10  cm3)17. Study participants had no concurrent illness, were not on any medi-
cation for the preceding 9 months and were not planning to conceive. For the purposes of this comparative study, 
all women fulfilled the NIH criteria for the diagnosis of PCOS.
In both cohorts, all women had prolactin, 17beta hydroxyprogesterone, thyroid function tests, and dehydroe-
piandrosterone sulfate (DHEAS) to exclude other confounding factors. Body mass index (BMI), waist circumfer-
ence, height and weight were performed according to WHO guidelines. Control women had regular menses and 
normal androgen levels thus excluding PCOS by either NIH or Rotterdam criteria.
Collection and analysis of blood samples. Blood samples were collected and were measured for the 
Middle Eastern population at the Chemistry Laboratory at Hamad Medical Corporation, Doha, Qatar, and 
for the UK population in the Chemistry Laboratory, Hull Royal Infirmary, UK that used the same laboratory 
platforms. TSH, prolactin, insulin, C reactive protein (CRP), DHEAS, and SHBG and measured by an immu-
nometric assay with fluorescence detection on the DPC Immulite 2000 analyzer using the manufacturer’s rec-
ommended protocol, as previously  described1. The Abbott testosterone method was performed for the Middle 
Eastern population within manufacturer’s specification throughout the sample collection (within run coefficient 
of variation (CV) 3.1%, within laboratory CV 3.6% at 2.6 nmol/L)1, whilst testosterone was measured by isotope 
dilution liquid chromatography-tandem mass spectrometry (Waters Corporation, Manchester, UK) in the UK, 
as previously  described9.
“The free androgen index (FAI) was calculated as the total testosterone × 100/SHBG. Serum insulin was 
assayed using a competitive chemiluminescent immunoassay performed on the manufacturer’s DPC Immulite 
2000 analyzer (Euro/DPC, Llanberis, UK). The analytical sensitivity of the insulin assay was 2 μU/ml, the coef-
ficient of variation was 6%, and there was no stated cross-reactivity with proinsulin. Plasma glucose was measured 
using a Synchron LX 20 analyzer (Beckman-Coulter), using the manufacturer’s recommended protocol. The 
coefficient of variation for the assay was 1.2% at a mean glucose value of 5.3 mmol/L during the study period. 
The insulin resistance was calculated using the HOMA method [HOMA-IR = (insulin × glucose)/22.5]”1. All 
analyses were undertaken according to current guidelines, regulations and quality control.
Statistical analysis. As described  previously4, data trends were visually evaluated for each androgen and 
non-parametric tests were applied on data that violated the assumptions of normality when tested using the 
Kolmogorov–Smirnov Test. Accordingly, comparative analysis evaluating androgen levels between PCOS cases 
and controls was performed using the non-parametric Mann–Whitney test. Significance was defined at α = 0.05. 
All analyses were done using IBM-SPSS version 24.0. All values are given as (mean ± SD) unless specified. No 
formal power analysis was undertaken as there is not previous literature to do so.
Ethics approval and consent to participate. The study was approved by the QBB IRB and the Ministry 
of Public Health in Qatar (Middle Eastern cohort) and the Newcastle & North Tyneside Ethics committee (UK 
cohort). All study participants signed an informed consent form prior to participation.
Consent for publication. All authors gave their consent for publication.
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18895  | https://doi.org/10.1038/s41598-020-75109-2
www.nature.com/scientificreports/
Results
The comparison between normal and PCOS subjects within the Middle  East3 and  UK18 subjects, respectively, 
within these databases for the increased cardiovascular risk indices (increased blood pressure, lower HDL, 
increased CRP) and increased androgens and insulin resistance seen in PCOS has been reported before.
When comparing the control women without PCOS between the Middle Eastern and UK cohorts (Table 1) 
it was seen that the age and BMIs were well matched, but waist measurement was higher in the UK (p < 0.04) 
whilst hip size was greater in the Middle Eastern population (p < 0.009). Systolic and diastolic blood pressure 
were higher in the UK cohort (p < 0.001), whilst testosterone (p < 0.02), glucose (p < 0.001), WCC (p < 0.001), 
HDL (P < 0.001), CRP (p < 0.001), insulin and insulin resistance (p < 0.001) were higher in the Middle Eastern 
cohort without PCOS.
When comparing the PCOS subjects (Table 2) it was seen that the BMI, waist and hip measurements, systolic 
and diastolic blood pressure (p < 0.001), and triglycerides (p < 0.015) were higher in the UK cohort. Testosterone 
(p < 0.001), HDL (P < 0.002), CRP (p < 0.001) were higher in the Middle Eastern population, whilst glucose, WCC, 
insulin and insulin resistance no longer differed between the 2 cohort of PCOS women.
Discussion
These data comparing the Caucasian UK cohort with the homogeneous Middle Eastern cohort confirm the 
prediction that women of the Middle East have a more severe hyperandrogenic  phenotype16 with an increased tes-
tosterone and FAI in women without PCOS and that is exacerbated in PCOS, highlighting the ethnic differences. 
These differences may in part contribute to the increase in hirsutism in the Middle East compared to  Europe13,19.
The increased cardiovascular risk indices, increased androgen levels and increased insulin that result from 
PCOS compared to normal women has been reported for both the UK and Qatari  databases3,7,18, indicating that 
there is an incremental worsening in these parameters irrespective of the ethnic baseline values, with PCOS. How-
ever, there were marked differences seen between the normal Caucasian and Middle Eastern women reported 
here. The Caucasian normal population had significantly higher systolic and diastolic blood pressures and a lower 
HDL that would suggest a comparatively higher cardiovascular risk and that would be in accord with  others14. 
However, the Middle Eastern women without PCOS had increased markers of inflammation with a higher white 
cell count and higher CRP that has been associated with increased cardiovascular  risk20,21. In addition, the Mid-
dle Eastern normal population had increased insulin levels and HOMA IR compared to the UK population, 
suggesting that they had an inherent increased insulin resistance despite their BMI and age being well matched.
In the comparison between the PCOS Caucasian and Middle Eastern populations, who were well matched 
for age, the differential in the insulin levels and HOMA seen in the normal population was lost and, in PCOS, 
both were increased, but did not differ between the populations. There was an increase in BMI for the Caucasian 
population that may have reflected the increase in systolic and diastolic blood pressure and triglycerides seen; 
Table 1.  Comparison between the normal Caucasian UK (n = 69) and Middle Eastern (n = 622) population for 
subject demographics, cardiovascular and metabolic indices. HDL high density lipoprotein, LDL low density 
lipoprotein, CRP C reactive protein, SHBG sex hormone binding globulin.
UK population Middle Eastern population
p-valueMean Std. Dev Median Range Mean Std. Dev Median Range
Age (years) 27.6 6.3 27.0 22.0 28.1 5.8 28.0 22.0 0.49
Height (cm) 167.5 6.9 168.0 38.0 160.1 6.4 160.6 41.2  < 0.001
Weight (kg) 97.1 23.8 94.0 106.7 78.0 16.5 80.5 81.8  < 0.001
BMI (kg/m2) 34.5 7.9 33.6 44.6 30.4 5.9 30.5 25.9  < 0.001
Waist (cm) 101.1 16.5 101.0 77.0 87.7 12.8 88.0 60.0  < 0.001
Hip (cm) 118.2 16.4 117.0 78.0 110.6 11.4 111.5 53.0 0.001
Systolic BP (mmHg) 121.8 14.4 120.0 74.0 109.0 10.9 109.0 53.0  < 0.001
Diastolic BP (mmHg) 77.1 10.7 77.0 54.0 72.8 7.9 72.0 45.0 0.001
Testosterone(nmol/l) 1.5 0.8 1.3 4.6 1.8 0.8 1.6 5.9  < 0.001
FAI 6.1 5.4 4.4 40.5 6.6 2.9 5.9 15.4 0.001
TSH (mU/l) 2.2 1.2 1.9 6.1 2.0 1.6 1.6 11.8 0.09
Glucose (mmol/l) 4.9 1.1 4.7 10.3 5.0 1.0 4.8 6.6 0.06
White cell count 7.1 2.0 6.9 10.8 7.5 1.9 7.4 9.2 0.07
Cholesterol (mmol/l) 4.8 1.0 4.6 4.4 4.7 0.7 4.6 3.8 0.72
Triglycerides(mmol/l) 1.6 1.3 1.2 8.4 1.2 0.6 1.0 2.6 0.02
HDL (mmol/l) 1.2 0.3 1.2 1.3 1.3 0.3 1.3 1.5 0.002
LDL (mmol/l) 2.9 0.9 2.8 4.1 2.8 0.7 2.9 3.7 0.91
CRP (mmol/l) 4.9 5.0 3.2 29.8 7.6 6.6 5.0 36.0  < 0.001
Insulin (μU/ml) 16.7 14.3 13.4 85.6 16.9 14.7 13.0 110.0 0.76
HOMA IR 4.1 6.0 2.7 54.9 4.0 4.3 2.6 32.1 0.54
SHBG (mmol/l) 33.4 21.2 27.0 110.6 28.5 10.7 27.0 58.0 0.67
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however, the Middle Eastern population maintained the higher androgen levels for both testosterone and the 
FAI, and the CRP was significantly increased as seen in the normal population. This suggests that the Caucasian 
population may overall have higher cardiovascular  risk14 compared to the Middle Eastern population. What this 
does suggest is that ethnically appropriate guidelines are needed for identifying anthropometric thresholds for 
better screening and diagnosis.
Glucose levels were significantly higher in the Middle Eastern normal compared to the Caucasian popula-
tion. This differential was lost in PCOS where glucose levels did not differ between the populations, though were 
higher than for normal in accord with the increase in diabetes reported for  PCOS7.
The strengths of this study were the relatively large cohorts for comparison that were age matched (and BMI 
matched in women without PCOS) and the complementary laboratory platforms for biochemical analysis; the 
exception to this was testosterone that was measured by immunoassay rather than gold standard tandem mass 
spectroscopy in the Middle East subjects that can be a problem due DHEAS cross reactivity in the immunoassay 
leading to potential assay interference  y22, but the number of subjects would have mitigated against the relative 
imprecision of the assay. Both populations were homogeneous, being either Caucasian or Middle Eastern. The 
limitations of this study were that the UK population, by attending a secondary care facility, may have introduced 
an element of bias compared to the general population that was captured in the Qatar biobank. The inability 
to undertake a baseline power analysis decreases the evaluation of type 1 and type 2 statistical errors, but the 
relatively large numbers of subjects and also the very highly significant values found (p < 0.001) would make the 
chance of such errors very small.
In conclusion, this study highlights that, in these differing ethnic populations, that whilst cardiovascular 
risk indices were increased for both PCOS cohorts, this may be for different reasons: with BMI, waist and hip 
measurements, systolic and diastolic blood pressure and triglycerides higher in the UK cohort while testosterone, 
HDL and CRP were higher in the Middle Eastern population. Insulin resistance did not differ between the 2 
PCOS populations despite differences in BMI.
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